Drugs / ALN-KHK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05761301 | Mar 2023 → Apr 2025 | type 2 diabetes mellitus | Alnylam Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-12-13 | Alnylam Pharmaceuticals | Results Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day alnylam.com ↗
Positive Initial Phase 1 Results with ALN-KHK Demonstrate Robust Target Engagement and an Encouraging Safety Profile, Supporting Continued Development as a Novel Treatment for Type 2 Diabetes Mellitus |
| 2022-12-21 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes alnylam.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-13 | Alnylam Pharmaceuticals | Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day alnylam.com ↗ |
| 2022-12-21 | Alnylam Pharmaceuticals | Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-KHK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05761301 ↗ |
| Route | Subcutaneous | “ALN-KHK will be administered by subcutaneous (SC) injection.” NCT05761301 ↗ |